Loading clinical trials...

Establishment of Multimodal-multiparametric Progressive Prediction Models for Thyroid Associated Ophthalmopathy | Clinical Trials | Clareo Health

COMPLETED

Establishment of Multimodal-multiparametric Progressive Prediction Models for Thyroid Associated Ophthalmopathy

NCT06585592•Shanghai Changzheng Hospital

View on ClinicalTrials.gov

Summary

Thyroid-associated ophthalmopathy (TAO) is an organ-specific autoimmune disease closely related to thyroid disease, which leads the incidence of orbital disease in adults and is the most common cause of diffuse toxic goiter (Graves disease, GD). The clinical manifestations of TAO are complex and varied. In severe cases, it may seriously impair visual function, affect daily life, and even cause corneal ulceration, perforation, and blindness. Therefore, a reasonable and effective treatment plan should be chosen according to the degree of TAO. The aim of this clinical study is to: 1. Found characteristic changes from baseline to the end of treatment. 2. Identify characteristic changes associated with treatment response. 3. Construct a multimodal and multiparameter prediction model by characteristic changes.

Eligibility

Age

18 - 80 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•According to the Bartley criteria，diagnosed TAO from 2017/1/1 to 2024/3/31
•Moderate to severe patients defined by EUGOGO
•CAS ≥4 (on the 7-item scale) for the study eye
•Completed orbital MRI at our hospital
•Received complete medical treatment and completed assessment at our hospital

Exclusion Criteria

•Anticipated need for intervention due to sight-threatening complications or other significant and acute deterioration in vision
•History of systemic (eg, oral or IV) steroid use with a cumulative dose equivalent to \< 1 g of methylprednisolone for the treatment of TAO.
•Any major illness/condition or evidence of an unstable clinical condition that, in the investigators judgment, will substantially increase the risk to the participant, or confound the interpretation of safety assessments, if they were to participate in the study
•Any other condition that, in the opinion of the investigator, would impair the ability of the participant to comply with the study procedures or impair the ability to interpret data from the participants participation in the study
•Pregnant or lactating
•Any other condition that,would impair the ability of the participant to undergo orbital MRI

Key Dates

Start Date

January 1, 2017

Primary Completion Date

March 31, 2024

Completion Date

March 31, 2024

Last Updated

July 1, 2025

Enrollment

500

ACTUAL participants

Conditions

Thyroid-Associated Ophthalmopathy

Sirolimus vs Corticosteroids in Treatment of Thyroid Eye Disease

NCT04936854

Thyroid-Associated Ophthalmopathy

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 1, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions